Corona Remedies is set to raise 655.4 crore via an offer for sale. The company focuses on specialist doctors, driving faster revenue growth than the Indian pharmaceutical market. Its sales grew by 13.6% compared to the market's 7.9%. Revenue and net profit have shown strong annual growth. Investors with a high-risk appetite can consider this IPO for the long term.
Nifty is expected to continue its uptrend, consolidating near record highs. Analysts suggest buying on dips, with a breakout potentially pushing the index towards 26,500-26,800. IndusInd Bank and PB Fintech are highlighted as top stock picks, with specific buy recommendations and targets.
Investors can now focus on accrual strategies for fixed-income portfolios. The Reserve Bank of India's interest rate outlook suggests lower returns from capital gains. Fund managers recommend short-term and liquid funds for near-term horizons. Longer horizons can consider short-duration and corporate bond strategies. This approach aims to earn returns from interest receipts.
The U.S. Department of Transportation is waiving part of a fine assessed against Southwest Airlines after the company canceled thousands of flights during a winter storm in 2022.
To ensure the recent interest rate reduction truly benefits the economy, the Reserve Bank of India may have to infuse a staggering 1.5 lakh crore into the financial system. This move is seen as vital to offset the liquidity drains caused by advance tax payments and possible forex market interventions.
